EGFR and lung carcinoma: The first is targeted therapy, which involves inhibitors like epidermal growth factor receptor (EGFR), activin receptor-like kinase (ALK), and reactive oxygen species (ROS)1 inhibitors designed to address driver gene mutations in lung cancer.